European Archives - Page 1429 of 1501 - European Medical Journal

IL-17 Inhibition: Emerging Perspectives in the Future Management of Axial Spondyloarthritis

The meeting was opened by Prof Atul Deodhar who introduced the prevalence, epidemiology, and clinical features of axial spondyloarthritis (axSpA), and…

IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis

Prof Philip Mease introduced psoriatic arthritis (PsA) with a particular emphasis on disease symptoms and an update on the status of current disease…

Pregnancy in Chronic Arthritis: Only a Matter of Planning

Chronic arthritis often affects women of childbearing age. The old concept that having chronic arthritis constitutes a major obstacle to women when…

Obesity and Osteoarthritis: More Than Just Mechanics

Osteoarthritis (OA) is the most common form of arthritis worldwide. It results in chronic pain, functional limitations, and significant social and…

Diffuse Large B Cell Lymphoma of the Foot in a Patient with Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) have an increased risk of developing malignant lymphomas, especially non-Hodgkin’s lymphoma (NHL).

Deciphering Ectopic Calcification: Contribution of the Rare, Inherited Disorder Pseudoxanthoma Elasticum

Soft connective tissue calcification is still an intriguing problem due to the high number of genes, proteins, and enzymes involved in the process.

Axial Spondyloarthritis: An Evolving Concept

Axial spondyloarthritis (AxSpA) is the prototype of a family of inter-related yet heterogeneous diseases sharing common clinical and genetic…

EMJ Rheumatology 2.1 2015

Hello, and a very warm welcome to this year’s edition of EMJ Rheumatology, your source for the latest discoveries and clinical data from the field.

Interview with Prof. Iain McInnes at EULAR 2015

Interview with Prof. Iain McInnes at the European League Against Rheumatism (EULAR) 2015 discussing his research on spondyloarthritis.

EMJ

PERSIST-2: Phase 3 trial of pacritinib versus best available therapy for myelofibrosis

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2…